Short Communication Open Access
Superior vena cava syndrome results in obstruction of the superior vena cava and commonly requires intervention. Stents are often used to increase the patency of the vena cava and to prevent reocclusion. The role of antithrombotic therapy and agents to use has been highly debated due to stent location, hematologic complications, and limited clinical evidence available on the topic. This commentary seeks to determine the appropriate choice, if any, for antithrombotic therapy after superior vena cava stent placement.
To read the full article Peer-reviewed Article PDF
| Peer-reviewed Full Article
Author(s): Sheena L. Hayes, Sara Lott, Michael J. Scalese*
Antithrombotic, Superior vena cava, Hematologic complications, Pharmacy Practice, Clinical Care Pharmacy